RecruitingPhase 2NCT04580420

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

Studying Primary hyperoxaluria

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Principal Investigator
Clinical Transparency (dept. 2834)
Novo Nordisk A/S
Intervention
DCR-PHXC(drug)
Enrollment
28 enrolled
Eligibility
All sexes
Timeline
2021 – 2032

Study locations (16)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04580420 on ClinicalTrials.gov

Other trials for Primary hyperoxaluria

Additional recruiting or active studies for the same condition.

See all trials for Primary hyperoxaluria →

← Back to all trials